Background: Low-grade inflammation is associated with depression, but studies of specific symptoms are relatively scarce. Association between inflammatory markers and specific symptoms may provide insights into potential mechanism of inflammation-related depression. Using longitudinal data, we have tested whether childhood serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels are associated with specific depressive symptoms in early adulthood.
Introduction
An association between low-grade inflammation and depression is well established. Metaanalyses of cross-sectional studies confirm that serum concentrations of pro-inflammatory cytokines [e.g., interleukin 6 (IL-6)] and acute phase proteins [e.g., C-reactive protein (CRP)] are elevated in acutely unwell patients with depression in comparison with controls (Dowlati et al., 2010; Goldsmith et al., 2016; Haapakoski et al., 2015; Howren et al., 2009 ). Furthermore, these elevated levels tend to normalise after recovery upon treatment with antidepressants, but continue to remain elevated in treatment resistant patients (Goldsmith et al., 2016; Maes et al., 1997; O'Brien et al., 2007) . Longitudinal studies reporting an association between higher levels of IL-6 and CRP in childhood/adulthood and subsequent development (Gimeno et al., 2009; Khandaker et al., 2014) and persistence (Khandaker et al., 2017b; Zalli et al., 2016) of depressive symptoms indicate that inflammation could be a cause, rather than simply a consequence of the illness.
Depression consists of a diverse range of symptoms. Inflammation may contribute to pathogenesis of specific components of the syndrome. Symptoms such as fatigue, psychomotor retardation, impaired sleep and change in appetite are often referred to as sickness behaviour or neurovegetative symptoms in the experimental animal literature (Dantzer et al., 2008; Miller et al., 2009; Raison et al., 2006) . The International Classification of Diseases 10th Revision (ICD-10) diagnostic criteria for depressive episode specifies these symptoms along with a few others as somatic symptoms of depression (see below) (WHO, 1992) . Somatic symptoms are different from psychological symptoms (e.g., hopelessness and guilt) of depression phenomenologically (WHO, 1992) and perhaps physiologically (Jokela et al., 2016) . Cross-sectional studies indicate that low-grade inflammation, as measured by elevated serum CRP levels, is associated with somatic symptoms (e.g., fatigue and impaired 7 sleep, activity levels) but not with psychological symptoms within the general population or in depressed patients (Jokela et al., 2016; Kohler-Forsberg et al., 2017) . However, these studies did not compare effect estimates for somatic and psychological dimensions directly.
Atypical features of depression, particularly increased appetite or weight, are associated with a higher number of genetic risk variants for body mass index (BMI) and levels of CRP and leptin (Milaneschi et al., 2017) . These findings support the idea that different depressive symptoms may have distinct pathophysiological mechanisms. Association between markers of inflammation and specific symptoms may provide important clues regarding potential mechanisms of inflammation-related depression. However, longitudinal studies of inflammatory markers and specific symptoms of depression are scarce.
Using data from the general population-representative Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort, we previously reported a longitudinal association between serum IL-6 levels in childhood at age 9 years and risk of depression and psychosis subsequently in early adulthood at age 18 years (Khandaker et al., 2014) . In order to gain further insight into the relationship between inflammation and depression, we present another longitudinal study based on the ALSPAC cohort that examines the relationships between IL-6 and CRP at age 9 years and 19 specific symptoms of depression assessed at age 18 years. In addition to using individual depressive symptoms, we created two latent variables representing somatic/neurovegetative and psychological symptom dimensions. We hypothesised that childhood inflammatory markers would be associated with specific depressive symptoms in early adulthood. 8
Methods

Description of Cohort and Sample Selection
ALSPAC is a general population-based birth cohort in the former Avon County in the South West region of England. 14541 pregnant women who were residents of the study catchment areas and had expected delivery dates between April 1st, 1991 and December 31st, 1992 were initially recruited into the cohort, resulting in 14062 live births. Additional children and parents were subsequently recruited into the cohort. Since age 7 years, the children attended annual clinical assessments during which they participated in various face-to-face interviews and physical tests. Detailed information about the ALSPAC cohort can be found on the study website (http://www.bristol.ac.uk/alspac), and the sample characteristics and methodology have been previously described (Boyd et al., 2013; Fraser et al., 2013) . For information on all available ALSPAC data, a fully searchable data dictionary is also available (http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary).
The risk sets for the analyses presented here were comprised of 5074 and 5086 participants who provided enough blood during clinical assessments at age 9 years to measure serum IL-6 and CRP levels, respectively ( Supplementary Figure 1) . Of the IL-6 risk set, 2731 participants with baseline IL-6 data had also attended the follow-up assessment for depressive symptoms at age 18 years; this analytic sample was used to assess associations between IL-6 and depressive symptoms. The analytic sample for CRP was similar (n = 2738). Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. 9
Measurement of Inflammatory Markers
Blood samples collected from non-fasting 9-year-old participants (mean age: 119.0 months; SD: 3.9 months) during clinical assessments were immediately centrifuged; serum samples were frozen at −80°C in 1 mL aliquots. After a median storage period of 7.5 years, IL-6 and CRP levels were assayed in 2008. There was no evidence of freeze-thaw cycles during storage.
Serum high sensitivity CRP levels were measured using an automated particle-enhanced immunoturbidimetric assay (Roche, Welwyn Garden City, UK). The minimum detection limit was 0.03 mg/L. CRP values in the entire sample (n = 5086) ranged from 0.01 to 67.44 mg/L; mean (SD) = 0.80 (2.72) mg/L. Serum IL-6 levels were measured using an enzymelinked immunosorbent assay (ELISA) (R&D Systems, UK). The minimum detection limit was 0.007 pg/mL. IL-6 values in the entire sample (n = 5074) ranged from 0.007 to 20.051 pg/mL; mean (SD) = 1.28 (1.59) pg/mL. All inter-assay and intra-assay coefficients of variation for IL-6 and CRP were less than 5%. No other inflammatory markers were measured from blood samples collected at age 9 years.
Serum IL-6 and CRP levels were analysed as categorical variables. The distributions of serum CRP values (n = 5086) and serum IL-6 values (n = 5074) were divided into three categories (bottom, middle and top thirds) based on their respective distribution tertiles (66 th and 33 rd percentiles for CRP were 0.37 and 0.14 mg/L, respectively; 66 th and 33 rd percentiles for IL-6 were 1.12 and 0.59 pg/mL, respectively). Statistical cut-offs were chosen due to the lack of accepted cut-off values for both IL-6 and CRP in defining low-grade inflammation in children. We carried out additional analysis using IL-6 quartiles. Serum IL-6 and CRP levels were analysed as standardised continuous variables (z-transformed values). 
Assessment of Depressive Symptoms at Age 18 Years
In assessment clinics held over the course of a few months, depressive symptoms were assessed in 18-year-old participants (mean age: 213.6 months; SD: 5.1 months) using a selfadministered computerized version of the Clinical Interview Schedule-Revised (CIS-R). CIS-R is a standardised and validated tool commonly used to assess depression and anxiety in community-based samples (Lewis et al., 1992) . As primary outcomes, we used all available specific depressive symptom level data gathered by CIS-R as individual variables. A total of 19 depressive symptoms were measured: fatigue, sleep disturbances, concentration difficulties, irritability, depressed/low mood, suicidality, worry, phobia, anxiety, panic, psychomotor change, change in appetite/weight, diurnal variation in mood, anhedonia, hopelessness, low self-esteem, self-blame, decreased libido and physical symptoms. Because we were interested in clinically significant depressive symptoms, we re-coded all depressive symptom as binary variables based on a clinically meaningful cut-off. Please see Supplementary Methods for full information on the data re-coding. Supplementary Table 1 presents a complete breakdown of responses to each symptom category, as originally coded by CIS-R, and for the re-coded variables.
Somatic/Neurovegetative and Psychological Symptoms of Depression
Somatic syndrome is recognised as a part of the diagnosis of depressive episode (F32) according to the ICD-10 diagnostic criteria for research (ICD-10: DCR-10) (WHO, 1992) .
We selected the following seven symptoms as somatic/neurovegetative based on this criteria: anhedonia, diurnal variation in mood, psychomotor change, change in appetite/weight, fatigue, sleep disturbances and decreased libido. The following seven symptoms were classified as psychological: depressed/low mood, concentration difficulties, irritability, hopelessness, self-blame, low self-esteem and suicidality. Each symptom was considered as a separate outcome variable. In addition, we carried out confirmatory factor analysis (CFA) to create two factor scores representing somatic/neurovegetative and psychological dimensions using the seven respective individual symptoms listed above.
Assessment of Covariates
We included age, sex, father's occupation, ethnicity, BMI and self-reported infections around blood collection as potential confounders. Because not every participant was exactly 18 years old at the time of outcome assessment, age was recorded at the time of outcome assessment in months and was used as a continuous variable. Sex was recorded at birth and treated as a binary variable. Father's occupation was recorded at birth according to the UK Office of National Statistics' socioeconomic classification system (Class I=professionals and higher managerial workers; II=intermediate occupations; IIIa=skilled non-manual occupations;
IIIb=skilled manual occupations; IV=partly skilled occupations; V=unskilled occupations) (Statistics, 1980) . This was re-coded as a binary variable with non-manual (I, II, and IIIa) and manual occupations (IIIb, IV, and V). Ethnicity was recorded at birth and originally coded as a categorical variable (White, Black Caribbean, Black African, Other Black, India, Pakistani, Bangladeshi, Chinese and Other). Ethnicity was re-coded as a binary variable (British White and Non-white) because the study sample was predominantly made up of British White participants (97.4%). BMI was assessed at the time of blood collection and recorded as a continuous variable. Self-reported infection status at the time or week before blood collection was recorded during the clinical assessment at age 9 years and used as a binary variable (i.e. infection present or absent).
Statistical Analysis
Comparison of Baseline Characteristics
Sociodemographic and other characteristics were compared among groups with low, medium and high IL-6 at age 9 years. One-way analysis of variance (ANOVA) was used for normally distributed continuous variables; Kruskal-Wallis test was used for non-normally distributed continuous variables; and Chi-squared test was used for categorical variables.
Association between Inflammatory Markers and Specific Symptoms of Depression
We used modified Poisson generalised linear regression with robust error variance to estimate the risk ratio (RR) and 95% confidence interval (CI) for each depressive symptom at age 18 years for participants in the top and middle, compared with the bottom, thirds of the serum IL-6 distribution at age 9 years. The same approach was taken for CRP. All regression models were adjusted for age, sex, father's occupation, ethnicity, BMI and self-reported infection. Adjusted RRs (95% CIs) were plotted on forest plots. P-values for unadjusted RRs for IL-6 were corrected for multiple testing using the Holm-Bonferroni method (Holm, 1979) . This method is similar to the Bonferroni, yet less stringent. Some have argued that this method is better than Bonferroni for public health research (Aickin and Gensler, 1996) . For a step-by-step guide on how this correction is calculated with an example, please see:
http://nebc.nerc.ac.uk/courses/GeneSpring/GS_Mar2006/Multiple%20testing%20corrections. pdf.
Association between Inflammatory Markers and Symptom Dimension Scores
First, we carried out CFA to test whether a unidimensional or two-factor model provided better fit for the symptom data (7 somatic/neurovegetative and 7 psychological symptoms) using the full information maximum likelihood (FIML) estimator. FIML allows for direct 13 comparison of both models. The results showed that two-factor model was marginally better than one-factor model (unidimensional: AIC=42376, BIC=42556; two-factor: AIC=42351, BIC=42538). We then added IL-6 into the model to test the association between IL-6 and two continuous latent variables/factors that represented somatic/neurovegetative and psychological dimensions. This was a structural equation model (SEM), which computed path coefficients, standard errors (SEs) and P-values for the association between IL-6 (standardised continuous variable) and these latent variables. The estimated coefficients are on the probit scale and represent changes in the symptom dimension standardised scores (Zscores) per SD change in IL-6 levels. In addition, we used a T-test to examine whether coefficients for somatic and psychological dimensions were significantly different from each other. 14 3. Results
Baseline Characteristics of Sample
Participants in the top third of IL-6 levels at baseline were more likely to be female, have higher BMI and have a self-reported infection around the time of blood collection at age 9 years. However, the distributions of age, British white ethnicity and father's non-manual occupations were similar across the thirds of IL-6 ( Table 1) .
Prevalence of Specific Symptoms of Depression at Age 18 Years
Data on 19 specific symptoms of depression were available for a total of 4568 participants.
Fatigue (31.5%), hopelessness (31.1%) and change in appetite/weight (28.1%) were the most prevalent symptoms while phobia (6.7%), decreased libido (4.5%) and panic (2.1%) were the least prevalent symptoms ( Supplementary Table 1 ).
Association between Inflammatory Markers and Specific Symptoms of Depression
IL-6 at age 9 years was associated with diurnal variation in mood, concentration difficulties, fatigue and sleep disturbances at age 18 years after adjusting for potential confounders (Figure 1; Supplementary Table 2 ). The adjusted RRs (95% CI) for diurnal variation in mood, concentration difficulties, fatigue and sleep disturbances were 1.75 (1.13-2.69), 1.50 (1.11-2.02), 1.31 (1.12-1.54), and 1.24 (1.01-1.52), respectively, for participants in the top, compared with the bottom, third of IL-6 at age 9. CRP was associated with fatigue, change in appetite/weight, and irritability in the unadjusted analysis; however, these associations became attenuated after controlling for potential confounders (Figure 2 ; Supplementary Table   3 ).
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Sensitivity analyses using quartiles of IL-6 showed that IL-6 was associated with fatigue, diurnal variation in mood, concentration difficulties and hopelessness after controlling for potential confounders for participants in the top quartile of IL-6 distribution compared with the bottom quartile. There was also trend level association of IL-6 with anhedonia, psychomotor change and low self-esteem. Please see Supplementary Table 4 . 
Association between Inflammatory Markers and Symptom Dimension Scores
SEM analysis testing the association between IL-6 and two latent variables representing depressive symptom dimensions showed that IL-6 was associated with both somatic/neurovegetative (co-efficient = 0.059, SE = 0.024, P = 0.013) and psychological dimensions (co-efficient = 0.056, SE = 0.023, P = 0.016); see Figure 3 . In other words, a SD change in IL-6 levels translated to a change in the Z-scores by 0.059 points for the somatic/neurovegetative dimension and 0.056 points for the psychological dimension. A ttest comparing the coefficients did not show a statistically significant difference (P = 0.379).
Figure 3: Structural Equation Model Testing the Association Between IL-6 and
Somatic/Neurovegetative and Psychological Symptom Latent Variables
Footnote: Confirmatory factor analysis computed somatic and psychological factors, which were used as outcome variables in relation to IL-6 in SEM. The path co-efficient for the association between IL-6 and the somatic factor was adjusted for the psychological factor, and vice versa.
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Effect of Multiple Testing
IL-6 was associated with 11 depressive symptoms before adjusting for potential confounders (Supplementary Table 2 ). Evidence for association remained for three symptoms (fatigue, sleep disturbances and hopelessness) after correcting observed P-values for multiple testing (Table 3) . 
Effect of Missing Data
To explore the potential impact of differential participant attrition over time, we compared participants in the IL-6 analytic sample (i.e. data present for both IL-6 and depressive symptom) with those in the missing sample (i.e. data present for IL-6 and missing depressive symptom). IL-6 levels, BMI, self-reported infection and British White ethnicity were similar between the analytic and missing samples (Online Supplementary Table 4 .). However, participants in the missing sample were more likely to be older, male and have a poorer socioeconomic status (fathers with manual occupations) compared to those in the analytic sample.
Effect of Acute Infection
We re-tested the associations between CRP and depressive symptoms after excluding 60 participants (1.2% of a total of 5086 participants) who had serum CRP levels >10mg/L, which we used as an indicator of acute infection. The results remained virtually unchanged. CRP was not associated with any depressive symptom after adjusting for potential confounders (Online Supplementary Table 5 ). 
Discussion
Using longitudinal data from a general population-representative birth cohort, we have examined associations between childhood IL-6 and CRP levels and specific symptoms of depression in early adulthood. Individual symptom level analysis indicated that IL-6 was associated with diurnal mood variation, concentration difficulties, fatigue and sleep disturbances after adjusting for potential confounders. Further analyses using latent variables showed that IL-6 was associated with both somatic/neurovegetative and psychological dimension scores. Adjusting for confounding had a more pronounced effect on the association between CRP and depressive symptoms; CRP was not associated with any depressive symptom after adjusting for confounders.
To our knowledge, this is one of the first general population-based longitudinal studies to investigate the association between inflammatory markers and specific depressive symptoms.
Low-grade inflammation, as defined by elevated serum concentrations of IL-6 and CRP, is associated with the diagnosis of depression (Dowlati et al., 2010; Goldsmith et al., 2016; Haapakoski et al., 2015; Howren et al., 2009) , depressive symptom severity (Jokela et al., 2016; Kohler-Forsberg et al., 2017; Moieni et al., 2015) and persistent depressive symptoms (Khandaker et al., 2017b; Zalli et al., 2016) . Cross-sectional studies have reported an association between inflammatory markers and somatic symptoms of depression such as fatigue, sleep disturbances and change in appetite and activity levels (Case and Stewart, 2014; Jokela et al., 2016; Kohler-Forsberg et al., 2017) . We have replicated some of these findings using a longitudinal design where inflammatory markers were measured years before depressive symptoms developed. These findings are consistent with the existing literature, which suggests that inflammation may be a cause for depressive symptoms, rather 24 than simply be a consequence of the illness (Gimeno et al., 2009; Khandaker et al., 2014; Khandaker et al., 2017a) .
In our analysis, inflammatory cytokine IL-6 was associated with so-called somatic/neurovegetative symptoms such as fatigue, sleep disturbances and diurnal variation in mood. This is consistent with findings from the NESDA cohort, which reported that inflammatory markers were specifically associated with somatic symptoms of depression such as fatigue, weight gain and sleep disturbances (Duivis et al., 2013) . Similarly, immunoactivation in animals and healthy volunteers leads to fatigue, psychomotor retardation and anhedonia, which are typical somatic symptoms according to ICD-10 diagnostic criteria for depressive episode (Brydon et al., 2008; Capuron et al., 2012; Eisenberger et al., 2010; Harrison et al., 2009; Harrison et al., 2015) . Features of sickness behaviour (e.g., fatigue)
develop rapidly in the majority of interferon-treated cancer patients who develop depression while psychological symptoms (e.g., low mood) develop slowly and relatively less frequently (Capuron et al., 2009; Capuron et al., 2002) . Inflammation-induced somatic/neurovegetative symptoms could be important mediators of the relationship between inflammation and depression. Experimental studies including clinical trials in humans are required to test this hypothesis.
One possibility is that somatic/neurovegetative symptoms affect mood by altering reward perception. Although the association between IL-6 and anhedonia was no longer statistically significant after adjusting for confounding within our dataset, previous experimental studies have reported an association between inflammation and anhedonia. In non-human primates chronic low-dose infusion of interferon-alpha leads to reduction in striatal dopamine release and anhedonia-like behaviour (Felger et al., 2013) . In patients with depression, plasma CRP concentration is associated with left basal ganglia glutamate levels, which, in turn, is associated with psychomotor slowing and anhedonia Haroon et al., 2016) . In healthy volunteers, experimental immuno-activation alters activation of rewardrelated brain regions (Brydon et al., 2008; Capuron et al., 2012; Eisenberger et al., 2010; Harrison et al., 2009; Harrison et al., 2015) , including reduction in the ventral striatum responses to hedonic reward (Capuron et al., 2012; Eisenberger et al., 2010) . In the future, RCTs and animal experimental studies could test whether altered reward perception mediate the relationship between somatic/neurovegetative symptoms and cognitive/psychological symptoms of depression after immune-modulation.
Association of inflammation with specific symptoms indicate that these symptoms could be important treatment targets and markers of treatment response in clinical trials of antiinflammatory drugs for depression. Selecting patients based on inflammation levels may be a fruitful strategy for clinical trials of anti-inflammatory drugs (Kappelmann et al., 2018; Raison et al., 2013) . Similarly, focusing on specific symptoms or symptom dimensions as outcomes may also be useful. Somatic symptoms such as fatigue and sleep disturbances have considerable negative impacts on daily functioning and quality of life in patients with physical illness (Janardhan and Bakshi, 2002) . There is little work on the impact of somatic symptoms on quality of life in patients with depression. Studies exploring the burden and impact of somatic symptoms in patients with depression are required.
We have defined certain depressive symptoms as 'somatic/neurovegetative' based on the ICD-10: DCR-10 criteria for depressive episode, somatic syndrome (see Methods) (WHO, 1992) . This is also informed by the experimental animal literature, where certain inflammation-induced symptoms such as anorexia, decreased motor activity, loss of interest and sleep disturbances are often described as sickness behaviour or neurovegetative symptoms (Dantzer et al., 2008) . The ICD-10 somatic symptoms of depression can be broadly seen as the human analogue of animal neurovegetative symptoms because these symptoms overlap, albeit not completely. However, we acknowledge that there are inconsistencies in the use of the term 'somatic' in the literature. It has also been used to refer to bodily distress, such as palpitations, tightness of the chest, pain, etc. (Kapfhammer, 2006) . This is not the same as the somatic syndrome currently defined by ICD-10: DCR:10 criteria for depression. Our use of the term is conceptually aligned with the ICD-10 definition of somatic syndrome in humans and inflammation-induced neurovegetative symptoms in animal studies, rather than bodily distress reflecting worry.
Strengths of this study include a relatively large general population-based sample, longitudinal study design and assessment of an array of depressive symptoms -19 in total.
However, there are some key limitations. Firstly, CRP was not associated with any depressive symptom which was surprising since IL-6 is a key inducer of CRP (Janeway et al., 2001) .
The use of non-fasting blood samples may have increased measurement error and is likely to have biased the findings toward the null. We adjusted our results for a number of potential confounders, but residual confounding could still be an alternative explanation for the observed associations between IL-6 and somatic symptoms. However, our work using Mendelian randomization analysis suggest that the association between IL-6/CRP and depression is likely to be causal (Khandaker et al., 2018a; Khandaker et al., 2018b) .
Serum IL-6 and CRP levels in our sample were generally low (Section 2.2), which could be due to the age of the participants. The reported mean serum CRP levels in adults (mean age: 57 years) within a large community-based Danish study were higher in comparison with 27 those in the relatively young ALSPAC sample; in the Danish sample, CRP levels further increased after a 10-year follow-up period (Wium-Andersen et al., 2013) .
Another significant limitation is the attrition of study participants between the time points of blood collection and depressive symptom assessment. Missingness was associated with older age, male sex and poorer SES. Older age and lower SES are both associated with depression.
An over-representation of individuals within these groups within the missing sample could introduce a bias towards the null. Therefore, we are likely to have underestimated the true association between IL-6 and specific depressive symptoms.
In summary, our findings indicate that childhood IL-6 levels are associated with specific symptoms of depression in early adulthood. Associations with so-called somatic/neurovegetative symptoms such as fatigue, sleep disturbances and diurnal mood variation indicate that these symptoms could be useful treatment targets and markers of treatment response in clinical trials of anti-inflammatory drugs for depression.
